Hormone Resistant Prostate Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate CancerInterventions: Drug: Carboplatin; Drug: Docetaxel; Other: Laboratory Biomarker AnalysisSponsors: University of Washington; National Cancer Institute (NCI)Not yet recruiting - verified October 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2015 Category: Research Source Type: clinical trials
